GlobalData on MSN2d
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
Pharmabiz2d
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
FiercePharma1d
Ideaya hires Gilead leader to head up commercialization push
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...
FiercePharma1d
Taking its best shot at Roche, Merck scores in phase 3 trial of subcutaneous Keytruda
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
Nasdaq5d
Bristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo plus Yervoy for the ...
Medpage Today on MSN1d
Immunotherapy Shows Promise in Downstaging Liver Tumors Prior to Transplant
Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...
Halozyme’s Competitive Edge: Butler’s Buy Rating Amid Emerging Competitors
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
Pharmabiz1d
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...